This role of SMYD3 is dependent on its catalytic activity and, specifically, its methylation of MAP3K2, which maintains constitutive activation of MEK/ERK signaling and alters the abundance of the EMT protein vimentin, contributing to PCa progression. Here, MAP3K2 is linked to posterior cortical atrophy.